DUBLIN, Oct. 23,
2024 /PRNewswire/ -- Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) today announced that it will report its 2024 third
quarter financial results on Wednesday,
November 6, 2024, after the close of the U.S. financial
markets. Company management will host a live audio webcast at
4:30 p.m. ET / 9:30 p.m. GMT to discuss 2024 third quarter
financial results and provide a business and financial update.
Audio webcast/conference call:
U.S. Dial-In
Number: +1 800 715 9871
Ireland Dial-In Number: +353 1800 943 926
Additional global dial-in numbers are available here.
Passcode: 5080203
Interested parties may access the live audio webcast via the
Investors section of the Jazz Pharmaceuticals website at
https://investor.jazzpharma.com/investors/events-presentations. To
ensure a timely connection, it is recommended that participants
register at least 15 minutes prior to the scheduled webcast.
A replay of the webcast will be available via the Investors
section of the Jazz Pharmaceuticals website at
https://investor.jazzpharma.com/investors/events-presentations.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc
(Nasdaq: JAZZ) is a global biopharma company whose purpose is to
innovate to transform the lives of patients and their families. We
are dedicated to developing life-changing medicines for people with
serious diseases — often with limited or no therapeutic options. We
have a diverse portfolio of marketed medicines, including leading
therapies for sleep disorders and epilepsy, and a growing portfolio
of cancer treatments. Our patient-focused and science-driven
approach powers pioneering research and development advancements
across our robust pipeline of innovative therapeutics in oncology
and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development
laboratories, manufacturing facilities and employees in multiple
countries committed to serving patients worldwide. Please visit
www.jazzpharmaceuticals.com for more information.
Contacts:
Investors:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717
Media:
Kristin
Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948
View original content to download
multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-2024-third-quarter-financial-results-on-november-6-2024-302284892.html
SOURCE Jazz Pharmaceuticals plc